Should I buy or sell Vaccitech stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VACC shares. View VACC analyst ratings or view top-rated stocks .

What is Vaccitech's stock price target for 2024?

2 brokerages have issued 12 month price objectives for Vaccitech's shares. Their VACC share price targets range from $3.25 to $12.00. On average, they expect the company's stock price to reach $7.63 in the next twelve months. This suggests a possible upside of 181.4% from the stock's current price. View analysts price targets for VACC or view top-rated stocks among Wall Street analysts .

How have VACC shares performed in 2024?

Vaccitech's stock was trading at $3.69 at the beginning of 2024. Since then, VACC stock has decreased by 26.6% and is now trading at $2.71. View the best growth stocks for 2024 here .

How were Vaccitech's earnings last quarter?

Vaccitech plc (NASDAQ:VACC) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.25. The firm earned $0.02 million during the quarter, compared to analysts' expectations of $1.65 million. Vaccitech had a negative net margin of 409.18% and a negative trailing twelve-month return on equity of 23.41%.

When did Vaccitech IPO?

Vaccitech (VACC) raised $110 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

How do I buy shares of Vaccitech?

Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VACC

Vaccitech (VACC) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free VACC Stock Alerts

$2.71

+0.11 (+4.23%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.53
▼
$2.77
50-Day Range: $2.33
▼
$5.00
52-Week Range: $1.64
▼
$5.10

Volume: 7,707 shs
Average Volume: 244,643 shs
Market Capitalization: $104.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.63

Get Vaccitech alerts:

Vaccitech MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 181.4% Upside
$7.63 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.41) to ($2.74) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.89 out of 5 stars

Medical Sector

819th out of 918 stocks

Pharmaceutical Preparations Industry

361st out of 402 stocks

3.3

Analyst's Opinion

Consensus Rating
Vaccitech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Vaccitech has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for VACC.

0.0

Dividend Strength

Dividend Yield
Vaccitech does not currently pay a dividend.
Dividend Growth
Vaccitech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VACC.

2.0

News and Social Media Coverage

News Sentiment
Vaccitech has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Vaccitech this week, compared to 0 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaccitech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.00% of the stock of Vaccitech is held by insiders.
Percentage Held by Institutions
Only 26.13% of the stock of Vaccitech is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Vaccitech are expected to decrease in the coming year, from ($2.41) to ($2.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vaccitech is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaccitech is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vaccitech has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Vaccitech Stock (NASDAQ:VACC)

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

VACC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VACC Stock News Headlines

April 17, 2024 | americanbankingnews.com

Vaccitech (NASDAQ:VACC) Trading Down 4.2%

April 6, 2024 | msn.com

London is a bad place to raise money, says life sciences tsar Sir John Bell

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 2, 2024 | seekingalpha.com

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

January 8, 2024 | markets.businessinsider.com

Positive Clinical Outlook and Strong Capital Position Justify Buy Rating for Barinthus Biotherapeutics

January 8, 2024 | finanznachrichten.de

Barinthus Biotherapeutics: Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

January 5, 2024 | finance.yahoo.com

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

December 22, 2023 | markets.businessinsider.com

Buy Rating for Barinthus Biotherapeutics: Promising Pipeline and Strategic Partnerships Signal Investment Opportunity

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

December 21, 2023 | markets.businessinsider.com

Barinthus Biotherapeutics Collaborates With CEPI And University Of Oxford For New MERS Vaccine

December 21, 2023 | finance.yahoo.com

New partnership aims to advance vaccine against MERS coronavirus

December 13, 2023 | finance.yahoo.com

Influenza Vaccine Market to grow by USD 2.93 billion from 2022 to 2027; North America to account for 54% of market growth - Technavio

November 28, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Barinthus Biotherapeutics (BRNS), Anavex Life Sciences (AVXL)

November 15, 2023 | finance.yahoo.com

Barinthus Biotherapeutics plc (BRNS)

November 9, 2023 | finance.yahoo.com

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

November 8, 2023 | money.usnews.com

Barinthus Biotherapeutics Plc. - ADR

November 7, 2023 | msn.com

Barinthus stock falls 18%, day after changing name from Vaccitech

November 6, 2023 | msn.com

Vaccitech rebrands as Barinthus, plans to present data at AASLD meeting

November 6, 2023 | finance.yahoo.com

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

September 28, 2023 | seekingalpha.com

SIRI, EC and PBTS among pre-market losers

September 26, 2023 | 247wallst.com

Morgan Stanley Downgrades Vaccitech

September 26, 2023 | uk.finance.yahoo.com

Innovative Therapeutic Cancer Vaccines Drive Unprecedented Growth in Global Cancer Vaccines Market to 2028

September 26, 2023 | seekingalpha.com

Vaccitech surges despite Morgan Stanley downgrade

September 26, 2023 | finance.yahoo.com

Vaccitech plc (NASDAQ:VACC) surges 85%; individual investors who own 44% shares profited along with institutions

September 25, 2023 | benzinga.com

Global Cancer Vaccines Market to Skyrocket, Projected to Reach $12.1 Billion by 2028

September 25, 2023 | marketwatch.com

Health Care Up on Defensive Bets -- Health Care Roundup

September 25, 2023 | msn.com

Morgan Stanley Downgrades Vaccitech plc - ADR (VACC)

See More Headlines

Receive VACC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VACC
CUSIP: N/A
CIK: 1828185
Web: www.vaccitech.co.uk
Phone: 44-18-6581-8808
Fax: N/A
Employees: 33
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.63
High Stock Price Target: $12.00
Low Stock Price Target: $3.25
Potential Upside/Downside: +181.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $5.34 million
Net Margins: -409.18%
Pretax Margin: -442.00%
Return on Equity: -23.41%
Return on Assets: -20.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.26
Quick Ratio: 15.26

Sales & Book Value

Annual Sales: $13.42 million
Price / Sales: 7.78
Cash Flow: $0.14 per share
Price / Cash Flow: 19.30
Book Value: $6.52 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 38,547,000
Free Float: 36,234,000
Market Cap: $104.46 million
Optionable: Not Optionable
Beta: -0.40

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. William J. Enright MBA (Age 60)
CEO & Director
Comp: $916.62k
Ms. Sarah Gilbert
Co-Founder
Mr. Adrian Hill Ph.D.
Co-Founder & Scientific Advisor
Ms. Gemma Brown (Age 33)
CFO & Company Secretary
Mr. Chris Ellis (Age 63)
Chief Operating Officer
Dr. Nadege Pelletier Ph.D. (Age 45)
Chief Scientific Officer
Mr. Graham Griffiths (Age 44)
Chief Business Officer
Ms. Elizabeth Eagling-Vose M.B.A.
Head of Clinical Operations
Bernie McDonald
Head of IP
Geoffrey Lynn
Senior Vice President of Synthetic Immunotherapies

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VACC Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaccitech stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VACC shares.
View VACC analyst ratings or view top-rated stocks.
What is Vaccitech's stock price target for 2024?: 2 brokerages have issued 12 month price objectives for Vaccitech's shares. Their VACC share price targets range from $3.25 to $12.00. On average, they expect the company's stock price to reach $7.63 in the next twelve months. This suggests a possible upside of 181.4% from the stock's current price.
View analysts price targets for VACC or view top-rated stocks among Wall Street analysts.
How have VACC shares performed in 2024?: Vaccitech's stock was trading at $3.69 at the beginning of 2024. Since then, VACC stock has decreased by 26.6% and is now trading at $2.71.
View the best growth stocks for 2024 here.
How were Vaccitech's earnings last quarter?: Vaccitech plc (NASDAQ:VACC) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.25. The firm earned $0.02 million during the quarter, compared to analysts' expectations of $1.65 million. Vaccitech had a negative net margin of 409.18% and a negative trailing twelve-month return on equity of 23.41%.

When did Vaccitech IPO?: Vaccitech (VACC) raised $110 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.
How do I buy shares of Vaccitech?: Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VACC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vaccitech (VACC) Stock Price, News & Analysis

Vaccitech MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Vaccitech Stock (NASDAQ:VACC)

VACC Stock Price History

VACC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VACC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™